Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 Next >
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers GSK MYGN PSNL QGEN
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN PSNL
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Earns 2024 Great Place To Work® Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN QGEN
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.